PTC Therapeutics Inc (PTCT) — Cash Flow-to-Debt Ratio
PTC Therapeutics Inc (PTCT) has a Cash Flow-to-Debt Ratio of -0.02x as of March 2026, meaning its operating cash flow of $-59.04 Million could theoretically repay 0% of its total liabilities ($3.05 Billion) in one year. See PTC Therapeutics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PTC Therapeutics Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for PTC Therapeutics Inc across 15 annual periods. For the full cash flow conversion analysis, see PTC Therapeutics Inc (PTCT) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for PTC Therapeutics Inc (2011–2025)
Year-by-year debt coverage analysis for PTC Therapeutics Inc. Check PTC Therapeutics Inc (PTCT) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | $711.20 Million | $3.12 Billion | ▲ +694.0% |
| 2024 | -0.04x | $-107.69 Million | $2.80 Billion | ▲ +34.2% |
| 2023 | -0.06x | $-158.42 Million | $2.71 Billion | ▲ +66.4% |
| 2022 | -0.17x | $-356.65 Million | $2.05 Billion | ▼ -33.9% |
| 2021 | -0.13x | $-251.33 Million | $1.94 Billion | ▼ -15.4% |
| 2020 | -0.11x | $-194.07 Million | $1.73 Billion | ▼ -17.3% |
| 2019 | -0.10x | $-98.64 Million | $1.03 Billion | ▼ -166.4% |
| 2018 | -0.04x | $-27.64 Million | $768.50 Million | ▲ +15.9% |
| 2017 | -0.04x | $-10.06 Million | $235.22 Million | ▲ +93.8% |
| 2016 | -0.69x | $-103.57 Million | $149.76 Million | ▲ +61.3% |
| 2015 | -1.79x | $-124.34 Million | $69.57 Million | ▼ -8.4% |
| 2014 | -1.65x | $-57.27 Million | $34.75 Million | ▲ +46.0% |
| 2013 | -3.05x | $-46.92 Million | $15.36 Million | ▼ -105.7% |
| 2012 | -1.49x | $-47.93 Million | $32.27 Million | ▼ -1922.4% |
| 2011 | -0.07x | $-20.77 Million | $282.75 Million | — |